ProQR Therapeutics NV

PRQR · NASDAQ

$1.38+$0.07 (+5.34%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.31

PRQR analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 12 analysts

Average $8.67 (+528.3% upside)

Low: $3.03
Now: $1.38
High: $15.75

Upgrades and downgrades

The latest rating actions, newest first

PRQR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Chardan Capital	Oct 1, 2026	Maintains	Buy	$3.00	38%
HC Wainwright & Co.	Oct 1, 2026	Maintains	Buy	$12.00 → $8.00	16%
B of A Securities	Aug 20, 2026	Initiates	Buy	$8.00	36%
Evercore ISI Group	Jun 29, 2026	Maintains	Outperform	$5.00 → $6.00	42%
Jones Trading	Jun 26, 2026	Maintains	Buy	$11.00 → $10.00	21%
Chardan Capital	Jun 26, 2026	Maintains	Buy	$4.00 → $3.00	38%
Chardan Capital	Apr 9, 2026	Maintains	Buy	$4.00	38%
Chardan Capital	Nov 4, 2025	Maintains	Buy	$4.00	38%

The case for and against

Updated Oct 18, 2026

Bull case

ProQR Therapeutics is attractive because its AX-0810 and AX-0811 programs now have early proof-of-concept and a biologically compelling NTCP-modulation thesis supported by human genetics, mechanistic bile-acid data, and encouraging preclinical efficacy. The company reported favorable safety with no SAEs to date, while the platform showed target engagement in healthy volunteers and meaningful improvements in liver bile acids and cholestasis scores, strengthening confidence that hepatic bile-acid reduction could translate into clinical benefit. Although the $50 mm offering at $1.81/share and $9.2 mm private placement increased dilution, the financing extends the runway from mid-27 into 2H28, supporting continued clinical progress through the January 2027 readout and mid-2028 interim analysis.

Bear case

ProQR Therapeutics is burdened by persistent cash burn and a likely need to raise additional debt or equity to fund research, regulatory work, and sales infrastructure, which could dilute shareholders or come with restrictive covenants. Its outlook is further weakened by uncertainty over clinical validation, FDA and EMA regulatory outcomes, and the possibility that future Phase Ib/II/III results or narrower label approvals will limit commercial potential. In a highly competitive RNA medicines landscape, where larger rivals have greater resources and stronger development experience, the company also faces patent risk, possible legal expenses, and the chance that new treatments could render its pipeline obsolete.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.